Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 8/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | TDO2 | P48775 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845290 | 0.91 | RECQL (0.47) | RECQLCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL31599788 | 0.83 | NAMPT (0.38) | MAPK1CYP1A2TDO2 | |
| SCHEMBL5946285 | 0.83 | RECQL (0.54) | RECQLCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL20858526 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM3MAPK1CYP1A2 | |
| SCHEMBL31429406 | 0.80 | RECQL (0.51) | RECQLCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL15687546 | 0.79 | MAPK1 (0.43) | CHRM1MAPK1CYP1A2TDO2CNR2 | |
| SCHEMBL31429277 | 0.79 | RECQL (0.44) | RECQLCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL31429286 | 0.77 | ADRA2A (0.48) | RECQLCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL31513256 | 0.75 | RECQL (0.40) | RECQLCHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL31429401 | 0.74 | KDM4E (0.47) | RECQLCHRM2CHRM1CYP1A2KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | METREA BIOSCIENCES INC (US) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250092014-A1 | COMPOUNDS AND METHODS OF ACTIVATING LIPOPROTEIN LIPASE | LPL, LIPA, PNLIP | RECQL 1592/4885CHRM2 1460/4885CHRM1 1399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.